Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

A Novel Irreversible Inhibitor of Acetylcholinesterase Specifically Directed at the Anionic Binding Site: Structure—Activity Relationships

B. BELLEAU and H. TANI
Molecular Pharmacology September 1966, 2 (5) 411-422;
B. BELLEAU
Department of Chemistry, University of Ottawa, Ottawa, Ontario
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. TANI
Department of Chemistry, University of Ottawa, Ottawa, Ontario
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Among a series of N,N-dimethyl-2-chloro-2-phenethylamines, tile prototype molecule carrying an unsubstituted phenyl ring has the unique property of irreversibly inactivating erythrocyte acetylcholinesterase when acetylcholine is the substrate. The active species responsible for this irreversible inhibition is the corresponding N,N-dimethyl-2-phenylaziridinium ion (DPA) which is generated spontaneously and quantitatively from the 2-chloroamine progenitor at neutral pH. The quaternary ion nature of DPA would allow for reversible addition complex formation with the anionic site of the enzyme and would precede slow alkylation of a nucleophile at that level. A significant stereoselectivity of the enzyme for the levo-isomer of DPA was demonstrated. Such optical selectivity is characteristic of the active surfaces of enzymes in general and of acetylcholinesterase in particular. When the phenyl ring carries substituents such as a 3'-hydroxy, 3'-methoxy, 3'-bromo, 4'-bromo, 4'-methoxy, or 3',4'-dibromo, only a reversible addition complex forms. The inability of these substituted analogs of DPA to alkylate the enzyme bears no relationship to the chemical reactivity of the aziridinium rings, but suggests rather that only the unsubstituted phenyl (as in DPA) can induce in the anionic compartment the type of fit conditioning covalent bond formation. In agreement with the view that DPA interacts with the anionic site of the enzyme, the competitive inhibitor tetramethylammonium iodide was shown to be effective in retarding irreversible inactivation. Neither prolonged dialysis nor incubation with 2-pyridine-aldoxime methochloride (PAM) can reactivate the enzyme after treatment with DPA. No correlation exists between the mode of interaction of DPA and its analogs with acetylcholinesterase and their effects at the adrenergic α-receptor level. The unique properties of DPA suggest applications in the determination of the active sequence at the anionic binding site of acetylcholinesterase.

ACKNOWLEDGMENTS The authors are grateful to the Defence Research Board, Ottawa, for the financial support of this work. Stimulating discussions with Drs. R. M. Heggie and R. McIvor were greatly appreciated. The cooperation of Mrs. Sheila Duke in the early phases of this work is gratefully acknowledged.

  • Copyright ©, 1966, by Academic Press Inc.

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology
Vol. 2, Issue 5
1 Sep 1966
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Novel Irreversible Inhibitor of Acetylcholinesterase Specifically Directed at the Anionic Binding Site: Structure—Activity Relationships
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

A Novel Irreversible Inhibitor of Acetylcholinesterase Specifically Directed at the Anionic Binding Site: Structure—Activity Relationships

B. BELLEAU and H. TANI
Molecular Pharmacology September 1, 1966, 2 (5) 411-422;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

A Novel Irreversible Inhibitor of Acetylcholinesterase Specifically Directed at the Anionic Binding Site: Structure—Activity Relationships

B. BELLEAU and H. TANI
Molecular Pharmacology September 1, 1966, 2 (5) 411-422;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
  • Benzbromarone relaxes airway smooth muscle via BK activation
  • Relapsed-leukemia model with NT5C2/PRPS1 hotspot mutations
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics